Clinical research of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome during peri-operative intervention operation period.
The objectives of this study are to explore the clinical effects of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) during peri-operative intervention operation period and to improve the level of clinical treatment. Ninety cases of high-risk NSTE ACS patients were randomly selected from January 2011 to April 2013 as the research objects, which were divided into two groups: the control group and the observation group. The control group received conventional aspirin, clopidogrel anticoagulation, coronary angiography, and percutaneous coronary interventional (PCI) treatment, while the observation group took tirofiban treatment in addition to the treatment of control group. The differences in major adverse cardiovascular events, TIMI flow grading, and complications of the two groups were observed after treatment. There were significant differences (P < 0.05) in the distal vascular blockage of major adverse cardiovascular events, intra-operative no-reflow, reoccurrence of acute myocardial infarction and stenocardia, and post-PCI TIMI flow grades 2 and 3. But in terms of bleeding complications, and TIMI flow grades 0 and 1 before PCI and after PCI, there was no significant difference (P > 0.05). Application of tirofiban treatment for high-risk NSTE ACS during the peri-intervention period is safe and effective, which can improve TIMI flow, increase tissue perfusion, and reduce postoperative complications.